We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hologic's (HOLX) Q2 Earnings Beat Estimates, Margins Fall
Read MoreHide Full Article
Hologic, Inc. (HOLX - Free Report) reported second-quarter fiscal 2019 adjusted earnings per share (EPS) of 58 cents, up 9.4% year over year. The bottom line surpassed the Zacks Consensus Estimate by a penny.
On a reported basis, the company recorded loss of $1.01 per share, narrower than the loss of $2.46 in the year- ago quarter.
Revenues in Detail
Revenues grossed $818.4 million in the reported quarter, up 3.7% year over year (up 5.2% at constant exchange rate or CER). The top line surpassed the Zacks Consensus Estimate by 1.6%.
Geographically, revenues in the United States rose 4.6% year over year to $615.5 million in the quarter. International revenues were up 1% (up 6.9% at CER) to $202.9 million, primarily on strong contribution from the Molecular Diagnostics, Breast Health and Surgical businesses.
Segments in Detail
Revenues at the Diagnostics segment rose 6% year over year (up 7.8% at CER) to $296.7 million in the quarter under review. Under this segment, Molecular Diagnostics revenues of $167.8 million rose 11.4% (up 12.8% at CER) fuelled by strong international performance. However, Cytology and Perinatal revenues of $115.5 million registered a 1.9% drop (up 0.3% at CER).
Revenues at the Breast Health segment increased 7.1% (up 8.4% at CER) to $321.5 million. This metric in the United States grew 8.8%. Internationally, Breast Health revenues rose 1.2% (up 6.9% at CER).
Revenues at the GYN Surgical business grew 2.8% (up 4.1% at CER) to $102.2 million. Medical Aesthetic business in the reported quarter registered revenues of $73.8 million, reflecting a 13.7% decline (down 12.1% at CER).
Revenues at Skeletal Health declined 1.4% (up 0.8% at CER) to $24.2 million.
Operational Update
In the fiscal second quarter, Hologic’s adjusted gross margin contracted 170 basis points (bps) to 61%. This downside was primarily due to an adverse geographic and product sales mix.
Adjusted operating expenses amounted to $272.8 million, up 2.2% year over year. Adjusted operating margin contracted 120 bps to 27.7%.
Financial Update
Hologic exited the second quarter of fiscal 2019 with cash and cash equivalents of $401 million compared with $311.1 million at the end of first-quarter fiscal 2019. Total long-term debt was $3.09 billion in the reported quarter compared with $604.4 billion at the end of the year-ago quarter. Year to date, net cash provided by operating activities was $238.1 million compared with $266.5 million a year ago.
Guidance Updated
Hologic has updated its fiscal 2019 financial guidance. The company now expects adjusted revenues in the range of $3.32-$3.34billion, up from the earlier-announced range of $3.30-$3.33 billion (a projection of 3.3-3.9% growth rate).
The Zacks Consensus Estimate for revenues is pegged at $3.32 billion, in line with the low end of the guided range.
The company envisions adjusted EPS of $2.41-$2.44 compared with $2.39-$2.43 stated previously (a projection of 8.1-9.4% growth rate). The consensus mark for the metric is pegged at $2.41, within the estimated range.
For third-quarter fiscal 2019, Hologic anticipates adjusted revenues of $825-$840, indicating 0.1-1.9% growth. The consensus estimate for revenues is $840.9 million, slightly above the projected range.
Adjusted EPS is predicted at 60-62 cents, reflecting annualized growth of 3.4-6.9%. The Zacks Consensus Estimate for fiscal third-quarter adjusted EPS is pegged at 62 cents, within the company’s forecasted range.
Our Take
Hologic exited the second quarter of fiscal 2019 on a solid note. The strong top-line growth was led by solid year-over-year rise in core businesses like Breast Health and Molecular Diagnostics. We are also upbeat about the recent launches like Aptima Mycoplasma genitalium assay and the Unifi Analytics business intelligence tool for mammography centers in the United States, Omnhysteroscope in Europe and Canada, and LOCalize wireless breast lesion localization system in Europe.
On the flip side, both margins contracted in the quarter under review.
Stryker delivered first-quarter 2019 adjusted EPS of $1.88, beating the Zacks Consensus Estimate by 2.2%. Revenues of $3.52 billion were in line with the consensus estimate.
Abbott reported first-quarter 2019 adjusted EPS of 63 cents, topping the Zacks Consensus Estimate by 3.3%. Worldwide sales totaled $7.54 billion, above the consensus estimate of $7.47 billion.
CONMED posted first-quarter 2019 adjusted EPS of 57 cents, which exceeded the Zacks Consensus Estimate of 54 cents. Revenues summed $218.4 million, outshining the consensus mark of $213 million.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year? Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3,
Zacks' Top 10s reached an even more sensational +181.9%.
Image: Bigstock
Hologic's (HOLX) Q2 Earnings Beat Estimates, Margins Fall
Hologic, Inc. (HOLX - Free Report) reported second-quarter fiscal 2019 adjusted earnings per share (EPS) of 58 cents, up 9.4% year over year. The bottom line surpassed the Zacks Consensus Estimate by a penny.
On a reported basis, the company recorded loss of $1.01 per share, narrower than the loss of $2.46 in the year- ago quarter.
Revenues in Detail
Revenues grossed $818.4 million in the reported quarter, up 3.7% year over year (up 5.2% at constant exchange rate or CER). The top line surpassed the Zacks Consensus Estimate by 1.6%.
Geographically, revenues in the United States rose 4.6% year over year to $615.5 million in the quarter. International revenues were up 1% (up 6.9% at CER) to $202.9 million, primarily on strong contribution from the Molecular Diagnostics, Breast Health and Surgical businesses.
Segments in Detail
Revenues at the Diagnostics segment rose 6% year over year (up 7.8% at CER) to $296.7 million in the quarter under review. Under this segment, Molecular Diagnostics revenues of $167.8 million rose 11.4% (up 12.8% at CER) fuelled by strong international performance. However, Cytology and Perinatal revenues of $115.5 million registered a 1.9% drop (up 0.3% at CER).
Hologic, Inc. Price, Consensus and EPS Surprise
Hologic, Inc. price-consensus-eps-surprise-chart | Hologic, Inc. Quote
Revenues at the Breast Health segment increased 7.1% (up 8.4% at CER) to $321.5 million. This metric in the United States grew 8.8%. Internationally, Breast Health revenues rose 1.2% (up 6.9% at CER).
Revenues at the GYN Surgical business grew 2.8% (up 4.1% at CER) to $102.2 million. Medical Aesthetic business in the reported quarter registered revenues of $73.8 million, reflecting a 13.7% decline (down 12.1% at CER).
Revenues at Skeletal Health declined 1.4% (up 0.8% at CER) to $24.2 million.
Operational Update
In the fiscal second quarter, Hologic’s adjusted gross margin contracted 170 basis points (bps) to 61%. This downside was primarily due to an adverse geographic and product sales mix.
Adjusted operating expenses amounted to $272.8 million, up 2.2% year over year. Adjusted operating margin contracted 120 bps to 27.7%.
Financial Update
Hologic exited the second quarter of fiscal 2019 with cash and cash equivalents of $401 million compared with $311.1 million at the end of first-quarter fiscal 2019. Total long-term debt was $3.09 billion in the reported quarter compared with $604.4 billion at the end of the year-ago quarter.
Year to date, net cash provided by operating activities was $238.1 million compared with $266.5 million a year ago.
Guidance Updated
Hologic has updated its fiscal 2019 financial guidance. The company now expects adjusted revenues in the range of $3.32-$3.34billion, up from the earlier-announced range of $3.30-$3.33 billion (a projection of 3.3-3.9% growth rate).
The Zacks Consensus Estimate for revenues is pegged at $3.32 billion, in line with the low end of the guided range.
The company envisions adjusted EPS of $2.41-$2.44 compared with $2.39-$2.43 stated previously (a projection of 8.1-9.4% growth rate). The consensus mark for the metric is pegged at $2.41, within the estimated range.
For third-quarter fiscal 2019, Hologic anticipates adjusted revenues of $825-$840, indicating 0.1-1.9% growth. The consensus estimate for revenues is $840.9 million, slightly above the projected range.
Adjusted EPS is predicted at 60-62 cents, reflecting annualized growth of 3.4-6.9%. The Zacks Consensus Estimate for fiscal third-quarter adjusted EPS is pegged at 62 cents, within the company’s forecasted range.
Our Take
Hologic exited the second quarter of fiscal 2019 on a solid note. The strong top-line growth was led by solid year-over-year rise in core businesses like Breast Health and Molecular Diagnostics. We are also upbeat about the recent launches like Aptima Mycoplasma genitalium assay and the Unifi Analytics business intelligence tool for mammography centers in the United States, Omnhysteroscope in Europe and Canada, and LOCalize wireless breast lesion localization system in Europe.
On the flip side, both margins contracted in the quarter under review.
Zacks Rank and Key Picks
Hologic currently carries a Zacks Rank #3 (Hold). Some better-ranked companies which reported solid results this earnings season are Stryker Corporation (SYK - Free Report) , Abbott Laboratories (ABT - Free Report) and CONMED Corporation (CNMD - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Stryker delivered first-quarter 2019 adjusted EPS of $1.88, beating the Zacks Consensus Estimate by 2.2%. Revenues of $3.52 billion were in line with the consensus estimate.
Abbott reported first-quarter 2019 adjusted EPS of 63 cents, topping the Zacks Consensus Estimate by 3.3%. Worldwide sales totaled $7.54 billion, above the consensus estimate of $7.47 billion.
CONMED posted first-quarter 2019 adjusted EPS of 57 cents, which exceeded the Zacks Consensus Estimate of 54 cents. Revenues summed $218.4 million, outshining the consensus mark of $213 million.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year? Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3,
Zacks' Top 10s reached an even more sensational +181.9%.
See Latest Stocks Today >>